DO EARLY CHANGES IN LEFT VENTRICULAR EJECTION FRACTION PREDICT LONG-TERM OUTCOMES AFTER TRANSCATHETER MITRAL VALVE REPAIR OF SECONDARY MITRAL REGURGITATION? THE COAPT TRIAL

Stamatios Lerakis,Annapoorna Kini,Federico M. Asch,Neil J. Weissman,Paul A. Grayburn,Saibal Kar,Kar,Scott Lim,Jacob M. Mishell,Brian Whisenant,Michael G. Rinaldi,Samir Kapadia,Vivek Rajagopal,Ian J. Sarembock,Andreas Brieke,Gilbert H.L. Tang,Aaron Crowley,Samin K. Sharma,JoAnn Lindenfeld,William T. Abraham,Michael J. Mack,Gregg W. Stone

DO EARLY CHANGES IN LEFT VENTRICULAR EJECTION FRACTION PREDICT LONG-TERM OUTCOMES AFTER TRANSCATHETER MITRAL VALVE REPAIR OF SECONDARY MITRAL REGURGITATION? THE COAPT TRIAL

2020

In the COAPT trial, transcatheter mitral valve repair with the MitraClip plus guideline directed medical therapy (GDMT) improved 2-year clinical outcomes in comparison to GDMT alone in symptomatic patients with heart failure (HF) and 3+ or 4+ secondary mitral regurgitation (SMR) due to LV

Keywords:

mitral regurgitation
Ejection fraction
Medicine
Cardiology
Transcatheter mitral valve repair
Internal medicine
long term outcomes
Guideline
medical therapy
Heart failure
MitraClip

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations